Recent developments highlight OneMedNet’s Nasdaq compliance restoration, expansion of healthcare data partnerships, FDA-related collaborations, and capital raising activities.

• OneMedNet regained Nasdaq compliance and is focusing on growth initiatives as of April 2026 [N1].
• The company expanded autoimmune data capabilities through a partnership with ViuHealth in February 2026 [N2].
• OneMedNet supported MlHealth 360 in obtaining FDA clearance for the Scaida BrainCT-ICH product in January 2026 [N3].
• Insider buying activity was reported in November 2025 [N4].
• The company raised approximately $3.7 million in private placement transactions in June 2025 [N7].
• OneMedNet expanded Datavant Connect capabilities to enhance healthcare data discovery and analytics in May 2025 [N8].
• Partnership with Protege was announced to improve real-time access to multimodal patient data for AI development in healthcare in April 2025 [N8].
• The company appointed Dr. Kenneth Alleyne as Chair of the Audit Committee in March 2025 [S1].

The company’s expanding partnerships and collaborations, including aiding FDA clearance for healthcare AI products and enhancing data discovery capabilities, demonstrate active business development and potential for increased adoption of its platform. The leadership’s healthcare IT experience and recent Nasdaq compliance restoration provide a foundation for operational stability and growth initiatives.

OneMedNet reported a net loss and negative earnings per share in the latest quarter, with liquidity ratios indicating current liabilities significantly exceed current assets, which may pose financial challenges. The company’s reliance on partnerships and regulatory approvals introduces execution risks. The competitive healthcare IT market and evolving regulatory environment may impact business performance and scalability.

OneMedNet’s moat is derived from its specialized healthcare data sharing platform and strategic partnerships with entities like ViuHealth, Datavant, and Protege, which enhance its data access and analytics capabilities. Its leadership’s deep expertise in healthcare IT and medical domains supports product development and market positioning. However, the company operates in a competitive and rapidly evolving healthcare technology landscape, which may limit barriers to entry.

• Financial Liquidity Risk: As of June 30, 2026, the company’s current ratio is 0.28 and cash ratio is 0.08, indicating limited liquidity and potential challenges in meeting short-term obligations.
• Regulatory and Compliance Risk: The company operates in a regulated healthcare environment and has recently regained Nasdaq compliance, highlighting ongoing regulatory and listing risks.
• Execution and Market Risk: Dependence on partnerships, regulatory approvals, and competitive pressures in healthcare IT may affect the company’s ability to execute its business strategy effectively.

• OneMedNet Corp is a healthcare IT company focused on healthcare data sharing and analytics.
• The company is publicly traded on Nasdaq under the ticker ONMD and has redeemable warrants (ONMDW).
• As of March 27, 2026, OneMedNet had 52,196,729 shares of common stock issued and outstanding.
• The company’s executive leadership includes CEO Aaron Green (since March 2024), CFO Robert Golden (since January 2025), and Chief Medical Officer Dr. Jeffrey Yu (founder and chairman).
• The Board of Directors consists of eight members with diverse healthcare, finance, and technology backgrounds.
• OneMedNet’s business involves partnerships to expand healthcare data capabilities, including autoimmune data through a partnership with ViuHealth and collaborations with Datavant and Protege to enhance real-world data access and AI development in healthcare.
• The company aided MlHealth 360 in obtaining FDA clearance for the Scaida BrainCT-ICH product.
• OneMedNet has raised approximately $3.7 million in private placement transactions as of June 2025.
• The company regained compliance with Nasdaq listing rules related to minimum bid price and listing standards in early 2025.
• Financial snapshot as of June 30, 2026 (Q2 2026): revenue of $292,000, net loss of $2,172,000, basic and diluted EPS of -$0.04.
• Liquidity ratios as of June 30, 2026: current ratio of 0.28 and cash ratio of 0.08, indicating current liabilities exceed current assets.
• Cash and cash equivalents totaled $358,000 as of June 30, 2026.
• The company’s filings include a 10-K/A amendment filed April 30, 2026, and a 10-Q filed August 14, 2026.
• The company’s leadership has extensive experience in healthcare IT, finance, and healthcare operations.
• Recent news highlights include Nasdaq compliance restoration, data expansion partnerships, FDA-related collaborations, and insider buying activity.